Hematology-American Society of Hematology Education Program

Article	Citations
Your chemo is no good here: management of high-risk MCL	96
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	90
The varieties of therapeutic experience: navigating treatment options for patients with PNH	65
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment	61
Mastocytosis demystified	50
Anticoagulation at the end of life: whether, when, and how to treat	42
Labor and delivery: DIC, HELLP, preeclampsia	40
On the horizon: upcoming new agents for the management of ITP	40
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	32
Neurological manifestations of MGUS	30
Recognizing, defining, and managing CAR-T hematologic toxicities	29
Challenges and opportunities in the long-term management of immune-mediated TTP	29
Inpatient recognition and management of HLH	28
Bispecific antibody therapies	28
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	26
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	26
New therapies in hemophilia: extend the half-life, mimic, or rebalance?	25
Where do immunotherapies stand in management of acute leukemia in adults?	25
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	24
Has PD-1 blockade changed the standard of care for cHL?	24
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	24
New approaches to tackle cytopenic myelofibrosis	23
Donor selection, graft engineering, and dosing oh my!	23
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL	23

Selecting initial therapy in CLL	22
Fitness and frailty in myeloma	22
Troubleshooting heparin resistance	22
Optimizing outcomes in secondary AML	22
Divergent paths: management of early relapsed follicular lymphoma	22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	21
BV and beyond: how to incorporate novel agents into PTCL management	21
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	21
MGCS: where do we stand today?	20
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	20
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?	19
How to assess hemostasis in patients with severe liver disease	19
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?	19
Hematology 2022—what is complete HLA match in 2022?	19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	19
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	19
How to manage hemostasis in patients with liver disease during interventions	19
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	19
How to diagnose and manage antiphospholipid syndrome	18
Consumptive coagulopathy in the ICU	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
Management of TKI-resistant chronic phase CML	17
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 202	17
What's new in hereditary hemorrhagic telangiectasia?	17
Atypical CML: diagnosis and treatment	17
Demystifying autoimmune HIT: what it is, when to test, and how to treat	17
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL	17
Thrombosis questions from the inpatient wards	16
Special considerations in GI bleeding in VWD patients	16
Management of limited-stage Hodgkin lymphoma	16
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	16
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma	16
Management of marginal zone lymphomas	16
Transplant in AML with measurable residual disease: proceed or defer?	15
Approaches to management of HIT in complex scenarios, including cardiac surgery	15
Pregnancy management for patients with bleeding disorders	15
Organ function indications and potential improvements following curative therapy for sickle cell disease	15
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
POEMS syndrome: diagnosis, treatments, and outcomes	14
Alloimmunization and hyperhemolysis in sickle cell disease	14
CNS prophylaxis in aggressive B-cell lymphoma	14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	14
Management of autoimmune hemolytic anemia	14
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing	14
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	14
Cytoreduction for ET and PV: who, what, when, and how?	13

Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	13
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma	13
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Pegylated interferon: the who, why, and how	13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	12
What makes a pediatric or young adult patient an appropriate transplant candidate?	12
Thrombocytopenia in pregnancy	12
Monoclonal gammopathy of renal significance from a hematologic perspective	12
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	12
Ph− ALL: immunotherapy in upfront treatment	12
Treatment of VTE in the thrombocytopenic cancer patient	12
Future directions in transplantation for aplastic anemia	12
Next-generation therapy for lower-risk MDS	12
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?	11
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS	11
Should we use bisphosphonates to treat bone complications in sickle cell disease?	11
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era	11
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS	11
Managing side effects: guidance for use of immunotherapies in multiple myeloma	11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	11
Clinical manifestations of telomere biology disorders in adults	11
Novel therapies upon failure of HMA plus venetoclax	11
What to know about rare B-cell malignancies in 2025	11
Warm autoimmune hemolytic anemia and the best treatment strategies	10
Barriers to accessing cellular therapy for patients receiving care in community practices	10
Approach to the patient with suspected hypereosinophilic syndrome	10
The role of stem cell transplant (auto and allo) in PTCL and CTCL	10
IV iron formulations and use in adults	10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	10
Sequencing bispecific antibodies and CAR T cells for FL	10
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	10
In 2022, which is preferred: haploidentical or cord transplant?	10
Porphyria cutanea tarda: a unique iron-related disorder	10
Managing patients with a history of arterial disease and new venous thromboembolism	10
The aging hemophilia patient	10
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD	10
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	9
Molecular surprises in evaluations of red cell disorders	9
Are transplant indications changing for myelofibrosis?	9
Long-term prophylaxis: what are our options and how to define success?	9
When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders	9
The approach of HMA plus VEN with or without BMT for all patients with AML	9
Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease	9
Implementation failure: thromboprophylaxis in ambulatory patients with cancer	9
What is the best induction for myeloma for the fit patient?	9
von Willebrand disease and heavy menstrual bleeding: when and how to test	9
Sequencing therapy in relapsed DLBCL	9
Updates in antithrombotic therapy in coronary and peripheral artery disease	9
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?	8
Amyloid consults do not have to be vexing	8
Multiple myeloma: a paradigm for blending community and academic care	8
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	8
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	8
Management of Fanconi anemia beyond childhood	8
Diagnosis of bleeding disorder of unknown cause: how many tests are enough to diagnose BDUC?	8
Risk-stratification in frontline CLL therapy: standard of care	8
(Un) Diagnosing von Willebrand disease	8
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	8
When should we use it? The role of brentuximab vedotin in 2024	8
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	8
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	8
Diagnosis and management of cold agglutinin disease	8
New definitions for antiphospholipid syndrome: ready for clinical use?	8
Novel platelet products including cold-stored platelets	8
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	8
From treatment to biology and back: managing iron overload in transfused hemoglobinopathies	8
Clonal hematopoiesis in frequent whole blood donors	8
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	8
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	8
Updates in the management of newly diagnosed chronic lymphocytic leukemia	8
Using disease-modifying therapies in sickle cell disease	7
When to consider inherited marrow failure syndromes in adults	7
New investigational combinations for higher-risk MDS	7
The first relapse in multiple myeloma: how to pick the next best thing	7
Newborn screening initiatives for sickle cell disease in Africa	7
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	7
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	7

Clonal evolution in inherited marrow failure syndromes predicts disease progression	7
Challenges to successful outcomes in AYAs with ALL and potential solutions	6
Sickle cell disease in India: the journey and hope for the future	6
Maintenance strategies for relapse prevention and treatment	6
How to manage ITP with life-threatening bleeding	6
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	6
Cellular therapy for multiple myeloma: what's now and what's next	6
New age HCT conditioning regimens: what works and why?	6
Renal manifestations of MGUS	6
The intersection of sickle cell disease, stigma, and pain in Africa	6
Potential and emerging therapeutics for HHT	6
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	6
Acute lymphoblastic leukemia in young adults: which up-front treatment?	6
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program . 2021;2021:621-627.	6
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	6
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	6
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?	6
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	6
Epidemiology and treatment of priapism in sickle cell disease	6
Ph+ ALL in 2022: is there an optimal approach?	6
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	6
Novel clinical care models for patients with sickle cell disease	6
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program . 2023;2023(1	6
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program . 2023;2023(1):573-580.	6
Transplantation in CML in the TKI era: who, when, and how?	6
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	6
Current use of bispecific antibodies to treat multiple myeloma	6
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	5
Dual-targeted regimens for the frontline treatment of CLL	5
Late complications and long-term care of adult CAR T-cell patients	5
Optimizing the “right” patient selection for treatment for sickle cell disease	5
Optimal approach to T-cell ALL	5
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	5
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	5
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	5
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	5
Ph+ ALL: new approaches for upfront therapy	5
The role of MRD monitoring and options for CLL management in relapsed/refractory disease	5
Buckle up! Managing surgery in patients with bleeding disorder of unknown cause	4
Givosiran: a targeted treatment for acute intermittent porphyria	4
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	4
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	4
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	4
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	4
Current use of CAR T cells to treat multiple myeloma	4
Mutational screening to improve the transplantation decision-making process in MDS	4
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	4
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	4
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	4
High-grade B-cell lymphomas: high difficulties to diagnose and treat?	4
Novel approaches to acute graft-versus-host disease prevention	4
Incorporating gonadal health counseling into pediatric care of sickle cell patients	4
The 5 most frequently asked questions about factor Xa inhibitors	4
Anticoagulants in hematologic malignancies: what is the data?	4
Approaches to optimize outcomes in transplant recipients	4
Allogeneic transplantation for advanced acute leukemia	4
Platelet components and bacterial contamination: hospital perspective 2022	4
Identifying and treating iron deficiency anemia in pregnancy	4
Deconstructing gene therapy in hemophilia for the clinician	4
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	4
Inflamed—HLH, MAS, or something else?	4
When sickle cell trait is not just trait: risk of VTE	4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	4
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	4
Molecular diagnostics 101: how to use genetic tests in classical hematology	4
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	4
Endless possibilities and how to exploit them? What is the optimal treatment sequence?	4